Thomas Spires
Senior Director, Translational Medicine Bristol Myers Squibb
Seminars
Wednesday 17th September 2025
Panel Discussion: Reducing Non-Responsiveness of RAS-Targeted Therapies by Delving into Mutation & Tissue Specific Impacts to Improve Drug Efficac
1:30 pm
• Uncovering factors within the tumor microenvironment which may result in non-responsiveness to
RAS-targeted therapies
• How do tissue specific interactions influence efficacy of RAS-targeting drugs?
• How do you successfully overcome or delay resistance to RAS-targeting therapies?
Tuesday 16th September 2025
Enhancing Anti-Tumor Immunity by Combining KRAS inhibition with Immune Checkpoint Blockade to Improve Treatment Responses
1:15 pm
- Overcoming the immunosuppressive tumor microenvironment (TME) of KRAS-mutant tumors
- Improving understanding of the influence KRAS inhibition on tumor immune responses to increase effectiveness of immune therapies
- Exploring combination strategies to overcome challenges posed by the TME and tumor stroma
